Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Johnson & Johnson fails to overturn $2.12 billion baby powder verdict, plans Supreme Court appeal

Published 03/11/2020, 20:24
Updated 03/11/2020, 22:15
© Reuters. FILE PHOTO: The company logo for Johnson & Johnson is displayed to celebrate the 75th anniversary of the company's listing at the NYSE in New York

© Reuters. FILE PHOTO: The company logo for Johnson & Johnson is displayed to celebrate the 75th anniversary of the company's listing at the NYSE in New York

By Jonathan Stempel

(Reuters) - Missouri's highest court on Tuesday refused to consider Johnson & Johnson's (N:JNJ) appeal of a $2.12 billion (£1.63 billion) damages award to women who blamed their ovarian cancer on asbestos in its baby powder and other talc products.

The Missouri Supreme Court let stand a June 23 decision by a state appeals court, which upheld a jury's July 2018 finding of liability but reduced J&J's payout from $4.69 billion after dismissing claims by some of the 22 plaintiffs.

Johnson & Johnson said it plans to appeal to the U.S. Supreme Court.

It said the verdict was the product of a "fundamentally flawed trial, grounded in a faulty presentation of the facts," and was "at odds with decades of independent scientific evaluations confirming Johnson's Baby Powder is safe, does not contain asbestos and does not cause cancer."

Kevin Parker, a lawyer for the plaintiffs, said in a statement: "Johnson & Johnson should accept the findings of the jury and the appellate court and move forward with proper compensation to the victims."

Johnson & Johnson said in May it would stop selling its Baby Powder talc in the United States and Canada.

The New Brunswick, New Jersey-based company said last month it faces more than 21,800 lawsuits claiming that its talc products cause cancer because of contamination from asbestos, a known carcinogen.

In its June decision, the Missouri Court of Appeals said it was reasonable to infer from the evidence that Johnson & Johnson "disregarded the safety of consumers" in its drive for profit, despite knowing its talc products caused ovarian cancer. It also found "significant reprehensibility" in the company's conduct.

Johnson & Johnson has faced intense scrutiny of its baby powder's safety following a 2018 Reuters investigative report that found it knew for decades that asbestos lurked in its talc.

Internal company records, trial testimony and other evidence show that from at least 1971 to the early 2000s, J&J's raw talc and finished powders sometimes tested positive for small amounts of asbestos. (https://www.reuters.com/investigates/special-report/johnsonandjohnson-cancer/)

© Reuters. FILE PHOTO: The company logo for Johnson & Johnson is displayed to celebrate the 75th anniversary of the company's listing at the NYSE in New York

Johnson & Johnson shares were up 2 cents at $138.71 in late afternoon trading on the New York Stock Exchange.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.